Interpace Diagnostics Faces Nasdaq Delisting

GenomeWeb
360Dx
Precision Oncology News

Interpace Diagnostics Faces Nasdaq Delisting

Nov 30, 2016

NEW YORK (GenomeWeb) – Interpace Diagnostics' stock faces delisting from the Nasdaq due to the company's failure to maintain a minimum of $2.5 million in stockholders' equity, according to a document filed yesterday with the US Securities and Exchange Commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

Interpace Diagnostics Faces Nasdaq Delisting

To read the full story....

Breaking News

At ESHG, Researchers Present New Noninvasive Prenatal Tests, Disease Recurrence Risk Study

USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

In Brief This Week: SpeeDx, Abbott

Bio-Techne Gets New York State Approval for Prostate Cancer Test

FDA Issues Draft Recommendations For Biotin Interference Testing

FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

Featured White Papers

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

BGI Genomics Continues to Grow Clinical Testing Business, Add Partnerships

Bio-Techne Gets New York State Approval for Prostate Cancer Test

ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

Sponsorships